公司资料
Gossamer Bio 股价、新闻与催化剂
- 股票代码:
- GOSS
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
0.17 USD (+13.12%)
收盘价
最后更新: 2026年8月24日
47M USD
市值
股价为何变动
As of Aug 24, 2026, GOSS closed up 13.1% at $0.1750. No new same-company headline was identified in the current news window.
公司概览
业务概览
Gossamer Bio is a biotechnology company focused on pulmonary and inflammatory disease. Its programs aim to address serious conditions in areas where targeted therapies can matter.
所在地与行业分类
Headquartered in the United States and listed on NASDAQ, Gossamer sits in specialty biotechnology.
商业模式特征
The company depends on clinical data, target validation, and the ability to build a focused respiratory and inflammation franchise.
生物医药行业定位
Gossamer is a catalyst-sensitive specialty name whose stock reacts to data, strategy, and execution.
未来催化剂
- Gossamer’s catalysts are seralutinib and the pulmonary-hypertension program, with the next update deciding whether the inhaled therapy can still build momentum. The company needs clean clinical progress to keep the story moving.
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。